A Study of DU-176b in Preventing Blood Clots After Hip Replacement Surgery
NCT ID: NCT00398216
Last Updated: 2019-02-26
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
903 participants
INTERVENTIONAL
2006-05-31
2007-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of the Efficacy and Safety of DU-176b in Preventing Blood Clots in Patients Undergoing Total Hip Replacement
NCT00107900
A Phase 2b Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty
NCT01203098
A Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty
NCT01181167
Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Hip Fracture Surgery
NCT01181141
A Phase 2b Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty
NCT01203072
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DU176b - action is the prevention of venous thromboembolism by the use of a Factor Xa inhibitor
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Able to provide written informed consent.
3. Must be scheduled for elective unilateral total hip replacement surgery. Only primary surgeries accepted.
4. If female, must be either one year post-menopausal, surgically sterile, or using medically accepted contraceptive measures as judged by the Investigator and in accordance with local regulatory requirements.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Daiichi Sankyo
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Daiichi Sankyo
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hartford, Connecticut, United States
Sarasota, Florida, United States
Austin, Texas, United States
Ajax, Ontario, Canada
Cambridge, Ontario, Canada
Guelph, Ontario, Canada
Kitchner, Ontario, Canada
Toronto, Ontario, Canada
Hellerup, , Denmark
Herlev, , Denmark
Hørsholm, , Denmark
Gyula, , Hungary
Kecskemét, , Hungary
Szeged, , Hungary
Riga, , Latvia
Krasnoyarsk, , Russia
Moscow, , Russia
Saint Petersburg, , Russia
Saratov, , Russia
Veliky Novgorod, , Russia
Volgograd, , Russia
Chernivtsy, , Ukraine
Dnipro, , Ukraine
Donetsk, , Ukraine
Kharkiv, , Ukraine
Kiev, , Ukraine
Lutsk, , Ukraine
Lviv, , Ukraine
Odesa, , Ukraine
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2006-000758-29
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
DU176b-PRT011
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.